Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 37.9% during trading on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. Approximately 1,160,600 shares changed hands during trading, an increase of 120% from the average daily volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Up 20.0 %
The stock’s fifty day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.07. The firm has a market cap of C$20.91 million, a PE ratio of -12.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What is a Low P/E Ratio and What Does it Tell Investors?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
- What is a Secondary Public Offering? What Investors Need to Know
- MarketBeat Week in Review – 01/06 – 01/10
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
